Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02684578. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Study identification
- NCT ID
- NCT02684578
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2016 (Type not available)
- Primary completion
- Apr 2022 (Actual)
- Completion
- Oct 2022 (Actual)
- Last update posted
- Jun 9, 2023
2016 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis | Davis | California | 95616 | — |
| Palo Alto Veteran Affairs Medical Center | Palo Alto | California | 94304 | — |
| Retinal Consultants Medical Group | Sacramento | California | 95819 | — |
| San Francisco Veteran Affairs Medical Center | San Francisco | California | 94121 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| California Retina Consultants | Santa Maria | California | 93454 | — |
| North Bay Vitreoretinal Consultants | Santa Rosa | California | 95403 | — |
| Retina Health Center | Fort Myers | Florida | 33907 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02684578, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2023 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.